A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri (Natalizumab) to Tecfidera (Dimethyl Fumarate)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Feb 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dimethyl fumarate (Primary) ; Natalizumab
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms STRATEGY
Sponsors Biogen

Most Recent Events

28 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
22 Dec 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
22 Dec 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight